SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its Q4 earnings report, where an EPS and revenue beat was overshadowed by cautious subscriber growth guidance and financial implications of the Warner Bros. Discovery acquisition, including a pause in share buybacks. This has ignited a fierce debate among investors, with many seeing the significant price drop as a generational 'buy the dip' opportunity for long-term content expansion, while others voice strong concerns about the deal's debt, halted buybacks, and Netflix's slowing growth in a competitive streaming market.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending after announcing an AI licensing partnership in Africa, which has ignited intense community discussion about its market potential. Many traders are focused on the stock's low float and high reported borrow fees, speculating on a significant short squeeze, while others express caution regarding its volatility.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is surging as the community keenly anticipates an imminent PMDA approval in Japan, following groundbreaking pancreatic cancer trial results demonstrating an 81% disease control rate. This pivotal regulatory decision, coupled with FDA module submission and growing institutional interest, underscores the revolutionary potential of their Alpha DaRT technology in oncology, driving widespread bullish sentiment.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing an "insane" rally to new all-time highs, fueled by escalating geopolitical tensions, particularly President Trump's tariff threats against Europe concerning Greenland, alongside broader concerns about US debt and dollar debasement. The community is sharply divided, with bulls celebrating significant gains and predicting much higher prices, while bears warn of a "bubble" and anticipate a "violent pullback" once tensions de-escalate. This robust surge highlights gold's role as a primary safe-haven asset amidst global uncertainty and questions surrounding fiat currency stability.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending amid conflicting analyst assessments, with recent downgrades from Bank of America and Goldman Sachs over valuation and SoftBank's large stake sparking community debate about motives. Despite this selling pressure, discussion highlights ARM's foundational role in AI, data centers, and its new 'Physical AI' robotics division, with many viewing current price action as an accumulation opportunity given its critical position in future tech.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending as recent significant contract wins with the U.S. Department of Health and Human Services and the U.S. Army are fueling investor optimism. The community is actively discussing how these federal deals, alongside the new CEO's deep government background, could signal a turnaround for the enterprise AI software provider. Furthermore, high short interest is prompting talk of a potential squeeze if this positive momentum continues.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid intense market focus on an upcoming high-profile address and recent geopolitical rhetoric, particularly concerning Greenland and global trade. The community is sharply divided, with many anticipating a quick market rebound while others brace for further downside, linking market direction to these unfolding events. This dynamic fuels significant volatility as participants actively debate the broader implications for the economy.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as a major institutional holder has registered its substantial stake for a potential sale, creating significant market buzz. This move has ignited a sharp debate among investors, with some viewing it as a bearish signal after a period of underperformance, while others see an attractive opportunity in this dividend-yielding consumer staple. The broader context includes anticipation of a planned company separation into distinct entities, which many believe could unlock value despite ongoing competitive pressures in the food sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.<h2 class="st-heading-2">What Is Lyme Disease?</h2>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.<h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.<h2 class="st-heading-2">Registered Direct Offering</h2>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user sounded optimistic about the stock.<stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

Equity

The company also announced the pricing of a $20 million registered direct offering. 


Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

Equities Analysts Offer Predictions for TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap raised their FY2025 earnings per share estimates for Tonix Pharmaceuticals in a report...

<ul class="summary-bullets"><li>Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.</li><li>The commercial rollout of Tonmya and buyback progress strengthened bullish sentiment around the company’s turnaround.</li><li>Some users speculated that the larger repurchase program could pressure short sellers or even hint at early buyout interest.</li></ul>Tonix Pharmaceuticals stock moved into sharp retail focus on Tuesday after the company expanded its share repurchase authorization by an additional $25 million, bringing the total buyback capacity to $35 million. The move came just one day after Tonix launched Tonmya, its newly approved fibromyalgia treatment, into U.S. pharmacies.<h2 class="st-heading-2">Buyback Expansion Sparks Bullish Retail Reaction</h2>On Stocktwits, retail sentiment for Tonix was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/148;" src="https://news.stocktwits-cdn.com/tnxp_ss_png_226c90b15a.webp" alt="tnxp ss.png" width="970" height="148"><figcaption>TNXP sentiment and message volume as of November 18 | Source: Stocktwits</figcaption></figure>In an 8-K filing on Tuesday, the company approved the increased buyback authorization, a signal retail traders interpreted as management showing confidence in Tonix’s valuation. One user said the upbeat tone of the filing, combined with clear progress on the Tonmya rollout, created a “blueprint for a rerating,” adding that companies don’t authorize larger repurchases unless they believe the stock is undervalued.<stembedurl>https://stocktwits.com/Doyoubelieveit/message/636681899</stembedurl>Another user highlighted Tonix’s turnaround, noting that investors who bought shares before FDA approval and commercialization were taking on significantly more risk. “we now have a FDA approved product, more cash than MCAP, huge pipeline, commercialization, grants, fast track designation, increased share buyback and many more,” the user said.<stembedurl>https://stocktwits.com/StockJayC/message/636677513</stembedurl><h2 class="st-heading-2">Short-Squeeze And Buyout Speculation Emerges</h2>The buyback news also triggered speculation about pressure on short sellers. One retail trader suggested that repurchases could force shorts to compete for shares, saying the company’s decision signaled it was “done with ATM dilution.”&nbsp;Another argued the enlarged buyback could “equal huge short squeeze,” while a separate user linked the authorization to potential M&amp;A interest, saying a repurchase program “makes sense if you’re being contacted about a buyout.”<stembedurl>https://stocktwits.com/TrendSetter67/message/636675726</stembedurl><stembedurl>https://stocktwits.com/shockfactor/message/636675727</stembedurl><stembedurl>https://stocktwits.com/Ripcurlinvestments/message/636677437</stembedurl><h2 class="st-heading-2">Tonmya Launch Adds Momentum</h2>Tonix&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-tnxp-stock-jump-10-today/cLPlTiTREef">began commercial distribution of Tonmya&nbsp;</a>on Monday, a prescription, non-opioid bedtime tablet approved for treating fibromyalgia in adults. The company said the drug is now available in U.S. pharmacies, calling the launch a “momentous day” for the estimated 10 million Americans living with fibromyalgia.The treatment received FDA approval in August based on two Phase 3 trials involving nearly 1,000 patients, which demonstrated reductions in daily pain and improvements in sleep, fatigue and overall functioning over 14 weeks. Side effects were mostly mild, including drowsiness, dry mouth and temporary oral numbness.<a href="https://stocktwits.com/symbol/TNXP">Tonix’s stock</a> has slumped 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’

Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.

<ul class="summary-bullets"><li>Tonmya’s FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients.</li><li>The most common side effects included mild mouth numbness or discomfort, altered taste, drowsiness, fatigue, dry mouth, and canker sores.</li><li>TNXP was among the top trending tickers on Stocktwits on Monday morning.</li></ul>&nbsp;Shares of Tonix Pharmaceuticals (TNXP) surged 10% on Monday after the company announced the launch of its new drug to treat Fibromyalgia.&nbsp;TNXP was among the top trending tickers on Stocktwits on Monday morning following the announcement. Tonix’s Tonmya is a prescription drug for the treatment of Fibromyalgia in adults. The company said that the non-opioid tablet, which can be taken once at bedtime, is now available in U.S. pharmacies.Fibromyalgia is a condition that causes widespread muscle and joint pain, often accompanied by fatigue. Its exact cause is unknown, but studies suggest that stress can play a role in triggering the symptoms.“The availability of Tonmya is a momentous day for Tonix, providing the estimated 10 million people living with fibromyalgia a novel treatment that has been shown to address the debilitating, core symptom of this disease, widespread pain,” said Seth Lederman, CEO of Tonix Pharmaceuticals.<h2 class="st-heading-2">Tonmya Trials</h2>Tonmya’s FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients, in which the drug showed meaningful reductions in daily pain over 14 weeks compared with placebo.A higher share of patients on Tonmya also achieved at least a 30% improvement in pain after three months. Findings from the RESILIENT Phase 3 trial highlighted improvements in symptoms, including sleep issues, fatigue, and overall patient functioning.The most common side effects included mild mouth numbness or discomfort, altered taste, drowsiness, fatigue, dry mouth, and canker sores.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, accompanied by ‘high’ message volumes. One Stocktwits user believes there is a potential for further upside before the market closes on Wednesday.<stembedurl>https://stocktwits.com/alecsalaur198/message/636442989</stembedurl>Another user believes the stock has long-term potential.<stembedurl>https://stocktwits.com/YourAverageStockGuy/message/636441761</stembedurl>TNXP shares have shed nearly half their value so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did TNXP Stock Jump 10% Today?

Tonix Pharmaceuticals on Monday announced the launch of its new drug to treat Fibromyalgia.

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its quarterly earnings results on Monday. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) jumped 4% in the pre-market session on Monday after its drug Tonmya received the U.S. Food and Drug Administration’s (FDA) approval for the treatment of fibromyalgia in adults.Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., mostly women, and symptoms include chronic widespread pain and fatigue, among others.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of">announced</a> the approval on Friday evening. Tonmya is a non-opioid, once-daily bedtime analgesic designed for rapid absorption into the bloodstream. It is also the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TNXP">Tonix</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘extremely high’ message volume. According to Stocktwits data, retail chatter around the stock jumped 72% over the past 24 hours and by 281% over the past seven days.<figure class="image"><img style="aspect-ratio:566/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_8_26_39_AM_png_c112eeec38.webp" alt="TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="566" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed hopes for a massive rally, adding that ‘this is a marathon not a sprint.’<stembedurl>https://stocktwits.com/AlwaysABullNeverABear/message/625581652</stembedurl>Another user said they see significant market potential for the drug.<stembedurl>https://stocktwits.com/GeneralAdam/message/625580421</stembedurl>In two late-stage trials, Tonmya significantly reduced fibromyalgia pain compared to placebo at 14 weeks. The drug was generally well-tolerated in late-stage trials, and a greater percentage of study participants taking Tonmya experienced a clinically meaningful improvement in their pain after three months, compared to placebo. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year.TNXP stock is up by 56% this year and by over 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said. 

Tonix Pharmaceuticals drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due&nbsp;Friday.If approved, the drug would be the first new treatment for fibromyalgia in more than 16 years. It’s taken as two 2.8 mg tablets placed under the tongue before bed.&nbsp;<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharma’s stock</a> jumped 32.9% to $14.79 on Tuesday, its best session in nearly five months, before edging up another 0.23% in after-hours trading.The centrally acting, non-opioid analgesic is designed for rapid transmucosal absorption, avoiding first-pass metabolism and reducing levels of a long half-life metabolite.The treatment earned Fast Track status from the FDA last year. In the late-stage RESILIENT trial, which enrolled 457 patients across 33 U.S. sites, those on TNX-102 SL reported a bigger drop in daily pain scores over 14 weeks compared with placebo, marking a 1.8-point reduction versus 1.2.&nbsp;It met all six secondary endpoints, and it's effective for sleep, fatigue, and general functioning. Side effects were mild, temporary, and generally limited to a tingling in the mouth or a bitter aftertaste. There were no serious drug-related adverse events.Tonix expects to roll out the treatment in the fourth quarter if it receives the green light, and stated that patents should protect U.S. sales until 2034-2035. The company is also testing the drug for other uses, including acute stress reaction, prevention of PTSD, Long COVID, alcohol use disorder, and agitation linked to Alzheimer’s disease.The rest of Tonix’s pipeline includes a Defense Department–backed study of TNX-102 SL for acute stress reaction, an anti-CD40L antibody called TNX-1500 aimed at preventing organ transplant rejection, and TNX-801, a live-virus vaccine candidate for mpox and smallpox.As of June 30, Tonix had $125.3 million in cash, plus additional funds from recent stock sales, which it stated will sustain operations through the third quarter of 2026.&nbsp;In the latest quarter, net revenue&nbsp;totaled $2 million, primarily from migraine drugs, while its net loss narrowed to $28.3 million from $78.8 million in the same period a year earlier.&nbsp;The company also launched its Move Fibro Forward campaign to raise awareness for fibromyalgia, a condition that affects millions of Americans and has long had limited treatment options.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 222% surge in 24-hour message volume, making it one of the platform’s top four trending equities.One user commented that $TNXP had delivered sixfold gains in six months, citing the second-quarter earnings beat and the upcoming FDA decision as reasons they considered it a “keeper.”<stembedurl>https://stocktwits.com/CCTVon/message/624881071</stembedurl>Another user remarked that despite past losses in the stock, the Fast Track status, lack of an advisory committee, and two strong Phase 3 results made the August 15 decision look promising.<stembedurl>https://stocktwits.com/SIRWINSALOT/message/624885454</stembedurl>Tonix Pharma’s stock has risen 81.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals (TNXP) drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due Friday. (Photo credit: Getty Images)

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

The late-stage candidate TNX-102 SL has received FDA Fast Track status and has delivered positive results in two pivotal Phase 3 trials, demonstrating meaningful pain reduction.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$17.04
Prev Close	$17.14
Open	$16.42
Dividend Yield	0.00%
50-Day Moving Average	$16.85
Beta	1.25
Avg. Volume	547,942.27
PE Ratio	-0.02

52-Week High	$69.97
52-Week Low	$6.76
Market Capitalization	$219.19M
EPS (Annual)	-$17,659.80
Price to Book	0.75
Revenue Per Employee	$124,617.28
Enterprise Value/EBITDA	N/A

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp